JP2019512251A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512251A5 JP2019512251A5 JP2018549452A JP2018549452A JP2019512251A5 JP 2019512251 A5 JP2019512251 A5 JP 2019512251A5 JP 2018549452 A JP2018549452 A JP 2018549452A JP 2018549452 A JP2018549452 A JP 2018549452A JP 2019512251 A5 JP2019512251 A5 JP 2019512251A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- host cell
- amino acid
- nucleic acid
- acid molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023045262A JP7746323B2 (ja) | 2016-03-23 | 2023-03-22 | Ｐｄ－１及び４－１ｂｂの融合タンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LULU93006 | 2016-03-23 | ||
| LU93006 | 2016-03-23 | ||
| PCT/EP2017/056931 WO2017162797A1 (en) | 2016-03-23 | 2017-03-23 | Fusion proteins of pd-1 and 4-1bb |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023045262A Division JP7746323B2 (ja) | 2016-03-23 | 2023-03-22 | Ｐｄ－１及び４－１ｂｂの融合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512251A JP2019512251A (ja) | 2019-05-16 |
| JP2019512251A5 true JP2019512251A5 (enExample) | 2019-09-19 |
| JP7250519B2 JP7250519B2 (ja) | 2023-04-03 |
Family
ID=55702054
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018549452A Active JP7250519B2 (ja) | 2016-03-23 | 2017-03-23 | Ｐｄ－１及び４－１ｂｂの融合タンパク質 |
| JP2023045262A Active JP7746323B2 (ja) | 2016-03-23 | 2023-03-22 | Ｐｄ－１及び４－１ｂｂの融合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023045262A Active JP7746323B2 (ja) | 2016-03-23 | 2023-03-22 | Ｐｄ－１及び４－１ｂｂの融合タンパク質 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11365237B2 (enExample) |
| EP (2) | EP3433269B1 (enExample) |
| JP (2) | JP7250519B2 (enExample) |
| CN (1) | CN109195985B (enExample) |
| AU (1) | AU2017236069B2 (enExample) |
| CA (1) | CA3017036A1 (enExample) |
| ES (1) | ES2962588T3 (enExample) |
| WO (1) | WO2017162797A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017014822A (es) | 2015-05-18 | 2018-04-30 | Tcr2 Therapeutics Inc | Composiciones y métodos para la reprogramación del tcr con proteínas de fusión. |
| FI3909972T3 (fi) | 2015-06-19 | 2024-05-03 | Sebastian Kobold | Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä |
| AU2017236069B2 (en) * | 2016-03-23 | 2021-04-08 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of PD-1 and 4-1BB |
| EP3544996A2 (en) | 2016-11-22 | 2019-10-02 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| KR20190096969A (ko) * | 2016-12-22 | 2019-08-20 | 윈드밀 테라퓨틱스, 인크. | 면역계를 조절하기 위한 조성물 및 방법 |
| US11352408B2 (en) | 2017-03-31 | 2022-06-07 | Toagosei Co., Ltd. | Antitumor peptide having PD-1 signal sequence and utilization thereof |
| SG11202013170RA (en) * | 2018-07-11 | 2021-01-28 | Kahr Medical Ltd | Pd1-4-1bbl variant fusion protein and methods of use thereof |
| KR102351041B1 (ko) * | 2018-12-19 | 2022-01-13 | 한국화학연구원 | 인간 lrrc24 단백질 유래 세포막 투과 도메인 |
| WO2020146423A1 (en) * | 2019-01-07 | 2020-07-16 | Thomas Jefferson University | Multi-functional fusion proteins and uses thereof |
| JP7676358B2 (ja) * | 2019-07-19 | 2025-05-14 | メモリアル スローン ケタリング キャンサー センター | 免疫療法のための融合ポリペプチド |
| CN115956086A (zh) * | 2020-05-06 | 2023-04-11 | 萨摩亚商柏沛生医股份有限公司 | 用于针对癌症及传染病的免疫疗法的融合蛋白 |
| WO2022036495A1 (en) * | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| EP4229079A4 (en) * | 2020-10-09 | 2024-12-11 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | METHODS AND COMPOSITIONS COMPRISING PD1 CHIMERIC POLYPEPTIDES |
| CN117321079A (zh) * | 2021-01-11 | 2023-12-29 | 优特力克斯有限公司 | 包含抗4-1bb抗体及pd-1蛋白或其片段的双特异性表位结合蛋白及其用途 |
| WO2023025779A1 (en) * | 2021-08-25 | 2023-03-02 | Medigene Immunotherapies Gmbh | Combination of antigen specific t cell receptors and chimeric co-stimulatory receptors |
| JP2025527657A (ja) * | 2022-08-23 | 2025-08-22 | メディジーン イミュノテラピーズ ゲーエムベーハー | Ｎｙ－ｅｓｏ－１特異的ｔ細胞受容体とキメラ共刺激受容体との組み合わせ物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2842368A1 (en) | 2011-07-29 | 2013-02-07 | The Trustees Of The University Of Pennsylvania | Switch costimulatory receptors |
| JP6074435B2 (ja) * | 2011-10-26 | 2017-02-01 | ナショナル キャンサー センター | 変異ｃｔｌａ４遺伝子移入ｔ細胞及びこれを含む抗がん免疫治療用組成物 |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| JP6493692B2 (ja) * | 2013-03-15 | 2019-04-10 | セルジーン コーポレイション | 修飾されたｔリンパ球 |
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| BR112015027567B1 (pt) * | 2013-05-03 | 2024-02-20 | Ohio State Innovation Foundation | Polipeptídeo, sequência de ácido nucleico isolada, vetor, método de obtenção de célula, uso de uma célula |
| JP2017513818A (ja) * | 2014-03-15 | 2017-06-01 | ノバルティス アーゲー | キメラ抗原受容体を使用する癌の処置 |
| MX2017001079A (es) * | 2014-07-24 | 2017-09-12 | Bluebird Bio Inc | Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma). |
| EP4205749A1 (en) * | 2014-07-31 | 2023-07-05 | Novartis AG | Subset-optimized chimeric antigen receptor-containing cells |
| US20180002435A1 (en) * | 2015-01-26 | 2018-01-04 | Cellectis | mAb-DRIVEN CHIMERIC ANTIGEN RECEPTOR SYSTEMS FOR SORTING/DEPLETING ENGINEERED IMMUNE CELLS |
| AU2015380397B2 (en) * | 2015-01-31 | 2021-10-21 | The Trustees Of The University Of Pennsylvania | Compositions and methods for T cell delivery of therapeutic molecules |
| AU2016228080B2 (en) * | 2015-03-02 | 2020-11-12 | Innovative Cellular Therapeutics Holdings, Ltd. | Reducing immune tolerance induced by PD-L1 |
| ES2979088T3 (es) * | 2015-03-05 | 2024-09-24 | Fred Hutchinson Cancer Center | Proteínas de fusión inmunomoduladoras y usos de las mismas |
| MX2017014822A (es) * | 2015-05-18 | 2018-04-30 | Tcr2 Therapeutics Inc | Composiciones y métodos para la reprogramación del tcr con proteínas de fusión. |
| CN104829733B (zh) | 2015-05-25 | 2018-06-05 | 广州百暨基因科技有限公司 | 抗原结合单元稳定的嵌合抗原受体及制备方法与应用 |
| FI3909972T3 (fi) * | 2015-06-19 | 2024-05-03 | Sebastian Kobold | Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä |
| WO2017004150A1 (en) * | 2015-06-29 | 2017-01-05 | The Johns Hopkins University | Immune checkpoint chimeric antigen receptors therapy |
| CA2997551A1 (en) * | 2015-09-04 | 2017-03-09 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| RU2018135819A (ru) * | 2016-03-11 | 2020-04-13 | Блубёрд Био, Инк. | Иммунные эффекторные клетки с отредактированным геномом |
| AU2017236069B2 (en) * | 2016-03-23 | 2021-04-08 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of PD-1 and 4-1BB |
| EP3759132A1 (en) * | 2018-03-02 | 2021-01-06 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| EP3774906A1 (en) * | 2018-03-28 | 2021-02-17 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
-
2017
- 2017-03-23 AU AU2017236069A patent/AU2017236069B2/en active Active
- 2017-03-23 US US16/087,262 patent/US11365237B2/en active Active
- 2017-03-23 WO PCT/EP2017/056931 patent/WO2017162797A1/en not_active Ceased
- 2017-03-23 CN CN201780031958.9A patent/CN109195985B/zh active Active
- 2017-03-23 JP JP2018549452A patent/JP7250519B2/ja active Active
- 2017-03-23 EP EP17713250.3A patent/EP3433269B1/en active Active
- 2017-03-23 ES ES17713250T patent/ES2962588T3/es active Active
- 2017-03-23 EP EP23193951.3A patent/EP4286522A3/en active Pending
- 2017-03-23 CA CA3017036A patent/CA3017036A1/en active Pending
-
2022
- 2022-06-08 US US17/835,936 patent/US12516101B2/en active Active
-
2023
- 2023-03-22 JP JP2023045262A patent/JP7746323B2/ja active Active
- 2023-11-16 US US18/510,940 patent/US20240247046A1/en active Pending